 |
53 Diseases |  |
490 Trials |
|
490 Trials |  |
8927 News |  |
| «12...1213141516171819202122...123124» |
- Tevimbra (tislelizumab-jsgr) / BeiGene, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Tislelizumab in combination with GEMOX and lenvatinib for conversion therapy of unresectable extrahepatic biliary tract carcinoma (eBTC): A prospective, single-arm, phase 2 study. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5473;
More patients were recruiting to further prove these results. Clinical trial information: ChiCTR2200056808.
- Avastin (bevacizumab) / Roche, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Transcatheter arterial chemoembolization combined with immune checkpoint inhibitors plus bevacizumab or lenvatinib in hepatocellular carcinoma: Results from a retrospective dual-center cohort study. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5471;
Transcatheter arterial chemoembolization (TACE) is globally acknowledged as the standard local treatment for intermediate HCC and remains the predominant care for advanced HCC, While lenvatinib (LEN) or the combination of bevacizumab (BEV) and atezolizumab is recognized as a first-line systemic therapy for HCC. TACE+ICI+BEV has demonstrated notable potential in increasing surgical conversion rate in the management of intermediate to advanced HCC, suggesting enhanced outcomes particularly in patients with superior liver function.
- Tevimbra (tislelizumab-jsgr) / BeiGene, Lenvima (lenvatinib) / Eisai, Merck (MSD)
A real-world experience of hepatic arterial infusion chemotherapy combined with tislelizumab and lenvatinib for unresectable hepatocellular carcinoma with type IV portal vein tumor thrombus. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5468;
Pts received HAIC of modified FOLFOX (oxaliplatin, 85 mg/m2; leucovorin, 400 mg/m2; 5-fluorouracil bolus, 400 mg/m2 on day 1; 5-fluorouracil infusion, 2400 mg/m2 for 46 h), lenvatinib (8 or 12 mg once daily for body weight, 60 or ?60 kg), and tislelizumab (200 mg q3w)...4%), HAIC+Tisle+Regorafenib (5... The combination of HAIC with tislelizumab and lenvatinib represents a promising efficacy and manageable safety for uHCC pts with Vp4, which supplements the trial data for Vp4-HCC with real world outcomes.
- Avastin (bevacizumab) / Roche, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Primary and secondary resistance to immune checkpoint inhibitors in hepatocellular carcinoma. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5431;
High AFP levels independently predict the survival of pts after primary resistance to immunotherapy. ICI-based maintenance therapy after resistance may provide a significant survival advantage for HCC pts.
- Imfinzi (durvalumab) / AstraZeneca, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Efficacy and safety of lenvatinib plus durvalumab combined with hepatic arterial infusion chemotherapy for unresectable intrahepatic cholangiocarcinoma. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5422;
Lenvatinib plus durvalumab combined with FOLFOX-HAIC showed promising antitumor activity and manageable AEs in patients with treatment-naive unresectable ICC. This regimen may be suitable as a novel first-line treatment option for this patient population.
- 5-fluorouracil / Generic mfg.
Hepatic artery infusion chemotherapy combined with immune checkpoint inhibitors and tyrosine kinase inhibitors for advanced hepatocellular carcinoma with portal vein tumor thrombus: A single center retrospective study. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5415;
This study further demonstrates the clinical benefit of HAIC plus ICIs and TKIs for HCC pts with PVTT. In the future, prospective studies are warranted.
- Enweida (envafolimab) / 3DMed, Tracon Pharma, Ascletis, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Envafolimab in combination with lenvatinib and albumin paclitaxel for previously treated advanced gastric/gastroesophageal junction adenocarcinoma: Preliminary analysis of a phase II, two-cohort study. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5382;
P2
In patients of advanced gastric cancer who have not previously received PD-1/PD-L1 inhibitors, this second-line combination therapy demonstrates promising preliminary effects. Clinical trial information: NCT06030934.
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
A retrospective analysis of efficacy and safety of lenvatinib combined with PD-1 inhibitor and chemotherapy in advanced biliary tract cancer (BTC). () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5378;
Patients with advanced BTC who received lenvatinib combined with PD-1 inhibitor plus oxaliplatin and gemcitabine (Gemox) chemotherapy were retrospectively screened. Lenvatinib combined with PD-1 inhibitor and Gemox chemotherapy provided remarkable efficacy with reasonable tolerability in advanced BTC patients.
- Tevimbra (tislelizumab-jsgr) / BeiGene, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Lenvatinib (Lenv) plus tislelizumab (Tis) combined with or without transarterial chemoembolization (TACE) in first-line treatment of unresectable hepatocellular carcinoma (uHCC): A prospective, non-randomized, open-label, phase II cohort study. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5365;
P1/2
More pts were recruiting to further prove these results. Clinical trial information: NCT05842317.
- Tevimbra (tislelizumab-jsgr) / BeiGene, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Neoadjuvant tislelizumab combined with lenvatinib plus transcatheter arterial chemoembolization in resectable hepatocellular carcinoma with high-risk of recurrence: A prospective, single-arm, phase II trial. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5344;
Tislelizumab, lenvatinib, and TACE were safe and showed promising efficacy as a neoadjuvant therapy for resectable HCC with high risk of recurrence. Clinical trial information: ChiCTR2200059574.
- Opdivo (nivolumab) / BMS, foslinanib immediate release (CVM-1118) / TaiRx
CVM-1118: A potent oral anti-vasculogenic mimicry (VM) agent in combination with nivolumab in patients with unresectable advanced hepatocellular carcinoma (HCC) () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5337;
P2
These data support further development of the combination of CVM-1118 and nivolumab in pts with unresectable advanced HCC. Clinical trial information: NCT05257590.
- Tevimbra (tislelizumab-jsgr) / BeiGene, Lenvima (lenvatinib) / Eisai, Merck (MSD)
A single-arm, prospective study on the efficacy and safety of TACE-HAIC combined with lenvatinib and tislelizumab in the treatment of unresectable hepatocellular carcinoma. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5325;
This therapy may be a treatment option for patients with unresectable hepatocellular carcinoma. Clinical trial information: ChiCTR2300067362.
- Zepsun (donafenib) / Suzhou Zelgen, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Comparing the efficacy and safety of TACE combined with donafenib or lenvatinib in the treatment of unresectable hepatocellular carcinoma. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5318;
The efficacy of donafenib and lenvatinib combined with TACE in the treatment of uHCC is equivalent. Furthermore, compared to lenvatinib combined with TACE, donafenib combined with TACE has higher safety.
- ETN101 / Etnova Therap
Preclinical antitumor efficacy of ETN101, a novel oral anticancer agent with Wnt/ () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5306;
We developed ETN101, a monotherapy that targets VEGFR2 and modulates the TME with the same mechanism as the combination therapy. ETN101 also showed excellent efficacy in preclinical study and secured a broad safety margin relative to the effective dose.
- Stivarga (regorafenib) / Bayer
Efficacy and safety of regorafenib plus ICIs as second-line treatment in advanced HCC post-frontline treatment failure: A real-world study from a single center. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5294;
8% of patients, sorafenib plus ICIs in three patients, apatinib plus ICIs, donafenib plus ICIs, and bevacizumab plus ICIs each in one patient... Regorafenib with ICIs is a promising and tolerable second-line treatment for advanced HCC after initial therapy failure.
- Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
Effect of triplet regimen (single-agent chemotherapy plus anti-PD-1 antibody and tyrosine kinase inhibitors) on survival compared to chemotherapy in the second-line treatment of advanced biliary tract cancer: A retrospective analysis. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5281;
Standard chemotherapy was Cohort B: mFOLFOX or irinotecan plus capecitabine... The retrospective analysis suggests that the triple regimen as second-line treatment for advanced BTC pts may help improve the efficacy and survival, and is worthy of further prospective exploration.
- Comparison of checkpoint inhibitor () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5277;
Among ICI combinations, better survival and response rates were reported with sintilimab + bevacizumab, atezolizumab + bevacizumab, and camrelizumab + rivoceranib. Therefore, these regimens should be preferred for treatment of advanced HCC as first line therapy in patients who can tolerate these regimens.
- Zepsun (donafenib) / Suzhou Zelgen, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Transarterial chemoembolization combined with donafenib or lenvatinib as first-line treatment for unresectable hepatocellular carcinoma: A single-center real-world retrospective study. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5274;
DON-TACE and LEN-TACE showed comparable efficacy as first-line therapies for uHCC patients. DON-TACE demonstrated a lower incidence of severe adverse events.
- Tevimbra (tislelizumab-jsgr) / BeiGene, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Second-line systematic strategy options for the progression of lenvatinib plus tislelizumab treating unresectable hepatocellular carcinoma: A retrospective study. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5269;
If the PFS of LEN+TIS was shorter than 8 months, Lenvatinib should be changed to Regorafenib, Tislelizumab could be not changed. And if the PFS of LEN+TIS was longer than 8 months, Lenvatinib and Tislelizumab should be changed at the same time, which seemed to achieve better results.
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
Lenvatinib, gemcitabine, and oxaliplatin for 67 patients with fibrolamellar carcinoma. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5226;
P=N/A
Our retrospective study of high-risk FLC, most multiply relapsed, pretreated, stage 4 and unresectable, showed that a prolonged and meaningful clinical response and acceptable quality of life with a chance for curative surgery is possible for many young patients thought to be incurable. Prospective trials are needed to confirm these results.
- Adherence for members taking oral oncolytic agents undergoing dose modification strategies. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_4622;
Dose modification was associated with significant decreases in adherence to oral oncolytic medications. Interventions designed to minimize dose modifications or to provide additional member support during a dose modification may optimize oral oncolytic adherence.
- Opdivo (nivolumab) / BMS, Lenvima (lenvatinib) / Eisai, Merck (MSD), Yervoy (ipilimumab) / BMS
Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC): First results from CheckMate 9DW. (Hall D1) - Apr 24, 2024 - Abstract #ASCO2024ASCO_3964;
P3
NIVO + IPI demonstrated statistically significant OS benefit vs LEN/SOR in pts with previously untreated uHCC, as well as higher ORR and durable responses with a manageable safety profile. These results support this combination as a potential new first-line SOC for uHCC.
- livmoniplimab (ABBV-151) / AbbVie, budigalimab (ABBV-181) / AbbVie
Phase 2 study of livmoniplimab in combination with budigalimab in patients with hepatocellular carcinoma. (Hall A; Poster Bd #: 164b) - Apr 24, 2024 - Abstract #ASCO2024ASCO_3918;
P1
The RP3D for livmo will be selected based on all available preclinical and clinical data. Enrollment began in July 2023 and up to 60 sites in ~7 countries will be included.
- GEMINI-Hepatobiliary: A phase 2 study of novel first-line immuno-oncology-based treatments in patients with advanced hepatobiliary cancers. (Hall A; Poster Bd #: 163b) - Apr 24, 2024 - Abstract #ASCO2024ASCO_3916;
P2
Early-phase studies have demonstrated the efficacy of volrustomig (volru; anti-PD-1/CTLA-4 bispecific humanized IgG1 monoclonal antibody [mAb]) in patients (pts) with non-small-cell lung cancer (NSCLC) and renal cell carcinoma, and of rilvegostomig (rilve; anti-PD-1/TIGIT bispecific humanized IgG1 mAb) in pts with NSCLC, along with manageable safety profiles...Pts will be treated with volru as monotherapy or in combination with bevacizumab or lenvatinib...Pts will be treated with gemcitabine + cisplatin with either rilve or volru...The study is currently recruiting at sites in the US, Asia, and Europe. GEMINI-Hepatobiliary master protocol design.
- Tyvyt (sintilimab) / Eli Lilly, Lenvima (lenvatinib) / Eisai, Merck (MSD)
PD-1 inhibitor (sintilimab) and lenvatinib plus TACE-HAIC as conversion therapy for initially unresectable HCC: A single-arm, phase 2 clinical trial (PLATIC). (Hall A; Poster Bd #: 103) - Apr 24, 2024 - Abstract #ASCO2024ASCO_3853;
P2
GEMINI-Hepatobiliary master protocol design. Sintilimab plus Lenvatinib and TACE-HAIC provided promising rate of conversion to resection in patients with initially unresectable HCC, with an acceptable TRAEs.
- Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Perioperative pembrolizumab and lenvatinib for resectable hepatocellular carcinoma: A single-arm, multi-center, phase II trial (NeoLEAP-HCC). (Hall A; Poster Bd #: 100) - Apr 24, 2024 - Abstract #ASCO2024ASCO_3850;
P2
Sintilimab plus Lenvatinib and TACE-HAIC provided promising rate of conversion to resection in patients with initially unresectable HCC, with an acceptable TRAEs. Pembrolizumab plus lenvatinib demonstrated promising anti-tumor efficacy with manageable toxicity in the neoadjuvant setting for resectable HCC.
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
Sorafenib plus hepatic arterial infusion of oxaliplatin and fluorouracil vs sorafenib plus transarterial chemoembolization for advanced hepatocellular carcinoma: A biomolecular exploratory, randomized, phase III trial (SHATA-001). (Hall A; Poster Bd #: 93) - Apr 24, 2024 - Abstract #ASCO2024ASCO_3844;
P3
This trial demonstrated SoraHAIC significantly improved OS over SoraTACE in patients with advanced HCC. However, patients with high FAD activity might have a better tumor response and survival benefit to SoraTACE than SoraHAIC.
- Avastin (bevacizumab) / Roche, Lenvima (lenvatinib) / Eisai, Merck (MSD), Tecentriq (atezolizumab) / Roche
Atezolizumab + bevacizumab versus lenvatinib as first-line systemic therapy for treatment of hepatocellular carcinoma in a real-world population: Outcomes from the HCC CHORD database. (Hall A; Poster Bd #: 91) - Apr 24, 2024 - Abstract #ASCO2024ASCO_3842;
This study provided real-world efficacy outcomes for AB directly compared to LEN in the first-line treatment of HCC in a Western country. AB was correlated with superior OS compared to LEN, but PFS and RR appear to be similar.
- Enweida (envafolimab) / 3DMed, Tracon Pharma, Ascletis, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Efficacy and safety of envafolimab plus lenvatinib combined with TACE in initially unresectable hepatocellular carcinoma: An open-label, single-arm, phase II study. (Hall A; Poster Bd #: 88) - Apr 24, 2024 - Abstract #ASCO2024ASCO_3839;
P2
AB was correlated with superior OS compared to LEN, but PFS and RR appear to be similar. Envafolimab combined with lenvatinib and TACE yielded promising survival outcomes and conversion rate with a manageable safety profile in uHCC, representing a potential and feasible conversion therapy regimen for this population.
- Tevimbra (tislelizumab-jsgr) / BeiGene, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Hepatic artery infusion chemotherapy (HAIC) combined with tislelizumab and lenvatinib for initial unresectable hepatocellular carcinoma (HCC) with portal vein tumor thrombus: A prospective, single-arm phase II trial. (Hall A; Poster Bd #: 83) - Apr 24, 2024 - Abstract #ASCO2024ASCO_3834;
Envafolimab combined with lenvatinib and TACE yielded promising survival outcomes and conversion rate with a manageable safety profile in uHCC, representing a potential and feasible conversion therapy regimen for this population. HAIC (FOLOFOX) combined with tislelizumab and lenvatinib afforded promising efficacy and safety in tumor control in patients with advanced HCC with PVTT in short-term observation and an eligible surgical conversion rate was observed.
- Zepsun (donafenib) / Suzhou Zelgen, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Stereotactic body radiotherapy (SBRT) combined with transcatheter arterial chemoembolization (TACE) and tyrosine kinase inhibitors (TKIs) versus TACE and TKIs alone for unresectable hepatocellular carcinoma (uHCC) with portal vein tumor thrombus (PVTT): A randomized controlled trial. (Hall A; Poster Bd #: 82) - Apr 24, 2024 - Abstract #ASCO2024ASCO_3833;
TKIs (sorafenib 0.4g bid; donafenib 0.2g bid; or lenvatinib 8mg/12mg qd, depending on body weight) were paused during the perioperative period of TACE (up to 4 times). In uHCC patients with PVTT, the combination of SBRT and TACE-TKIs showed significant survival benefit without the identification of any severe safety concerns.
- Avastin (bevacizumab) / Roche, Lenvima (lenvatinib) / Eisai, Merck (MSD), Tecentriq (atezolizumab) / Roche
Predictors of short-term death and long-term survival in advanced hepatocellular carcinoma (HCC) treated with contemporary tyrosine kinase inhibitors (TKI) or immunotherapy: A multicenter analysis from the HCC-CHORD consortium. (Hall A; Poster Bd #: 78) - Apr 24, 2024 - Abstract #ASCO2024ASCO_3829;
This study supports higher ALBI grade, MVI and distant metastases as predictors of STD, while lower ALBI grade, absence of MVI and lack of distant metastases were predictive of LTS in HCC patients treated with contemporary TKIs or immunotherapy combination regimens. These predictors may help guide treatment decisions in patient populations underrepresented in clinical trials, including patients with Child-Pugh B7 score who are often excluded.
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
ctDNA analysis of patients (pts) with unresectable hepatocellular carcinoma (uHCC) treated with lenvatinib (LEN) or sorafenib (SOR) as 1L therapy. (Hall A; Poster Bd #: 74) - Apr 24, 2024 - Abstract #ASCO2024ASCO_3825;
P3
TERT, TP53, and CTNNB1 MUT had little effect on tumor response in either treatment arm; TP53 MUT appeared to be a factor for poor OS prognosis in both arms. Further analysis is needed due to the differences in baseline characteristics between ctDNA and ITT pts, and the difference in sample size between arms.
- Lenvima (lenvatinib) / Eisai, Merck (MSD), Tecentriq (atezolizumab) / Roche
RNA expression-based hypoxia score as a prognostic and predictive biomarker in hepatocellular carcinoma. (Hall A; Poster Bd #: 6) - Apr 24, 2024 - Abstract #ASCO2024ASCO_3761;
HS-H tumors has worse OS that may be improved with Atezo, whereas HS-L tumors may respond better to Soraf. HS is a potential prognostic and predictive biomarker in HCC that deserves validation in orthogonal data sets and prospective studies.
- Cotellic (cobimetinib) / Exelixis, Roche, Tecentriq (atezolizumab) / Roche
Cobimetinib plus atezolizumab for RAS and NF1/2-mutated poorly differentiated thyroid carcinoma. (Hall A; Poster Bd #: 422) - Apr 24, 2024 - Abstract #ASCO2024ASCO_3556;
P2
However, SELECT trial did not delineate responses by driver mutations. This combination could thus be considered in selected patients at high risk of complications with antiangiogenic KIs.
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
Patients with radioiodine-refractory differentiated thyroid cancer (RAI-R DTC) with BRAF V600E and/or K601E mutation status: A real-world view of effectiveness of lenvatinib monotherapy. (Hall A; Poster Bd #: 414) - Apr 24, 2024 - Abstract #ASCO2024ASCO_3548;
In this US real-world experience, the effectiveness of lenvatinib is consistent across a diverse cohort of RAI-R DTC patients with BRAF-mutated, WT, and BRAF untested tumors. This has implications for the first-line use of lenvatinib in BRAF mutated patients.
- Tevimbra (tislelizumab-jsgr) / BeiGene, Lenvima (lenvatinib) / Eisai, Merck (MSD)
BGB-A317-212: A multicenter, open-label, phase II study to evaluate the efficacy and safety of tislelizumab in combination with lenvatinib in patients with selected solid tumors. (Hall A; Poster Bd #: 89) - Apr 24, 2024 - Abstract #ASCO2024ASCO_3011;
P2
Tislelizumab plus lenvatinib had a manageable safety profile and showed preliminary antitumor activity in pts with selected tumor types. Longer follow-up is needed to further investigate the potential of this combination to benefit pts with advanced solid tumors.
- E7386 / Eisai, PRISM Pharma, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Dose-expansion part of a phase 1b global study of E7386 in combination with lenvatinib (LEN) in patients (pts) with hepatocellular carcinoma (HCC) and other solid tumors including endometrial cancer (EC). (Hall A; Poster Bd #: 309b) - Apr 24, 2024 - Abstract #ASCO2024ASCO_2140;
P1
Study sites will include the United States, France, Republic of Korea, Japan, and Taiwan. As of February 5, 2024, 46 pts with HCC and 16 pts with EC have enrolled.
- Halaven (eribulin mesylate) / Eisai, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Phase II study of the combination of lenvatinib (L) and eribulin (E) in advanced solid tumors. (Hall A; Poster Bd #: 303) - Apr 24, 2024 - Abstract #ASCO2024ASCO_2129;
P2
Although manageable, neutropenia emerged as a notable adverse effect. These findings underscore the potential of this combination as a therapeutic strategy for advanced solid tumors, warranting further clinical investigation.
- AFT-50 EndoMAP: A phase IB/II multicohort study of targeted agents and/or immunotherapy for patients with recurrent or persistent endometrial cancer (EC). (Hall A; Poster Bd #: 502b) - Apr 24, 2024 - Abstract #ASCO2024ASCO_1954;
P1/2
The Atezo+bevacizumab (biomarker unmatched) and Atezo+ipatasertib (PIK3CA/PTEN/AKT1-altered tumors) cohorts have completed accrual...AFT-50B pts will be eligible for inavolisib (PIK3CAm/PTEN and AKT1wt-altered tumors) + letrozole or giredestrant + abemaciclib (RB1wt, estrogen receptor positive tumors)...As a platform study, additional arms may be added, as supported by evolving understanding of EC and molecular targets. EndoMAP is actively enrolling at 20 sites in the US with a target of 25 sites nationwide.
- Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
The molecular landscape of pembrolizumab and lenvatinib treatment in endometrial cancer. (Hall A; Poster Bd #: 483) - Apr 24, 2024 - Abstract #ASCO2024ASCO_1924;
Among TP53-mt patients, ARID1A-mt is associated with improved pembro-lenv survival but not in pembro alone. Our findings suggest a need to readdress when to use lenvatinib in TP53-mt patients and further explore genomic alterations that may promote treatment response to optimize use of this agent in endometrial cancer.
- Kaitanni (cadonilimab) / Akesobio, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Cadonilimab plus lenvatinib in patients with advanced endometrial cancer: A multicenter, single-arm, phase II trial. (Hall A; Poster Bd #: 471) - Apr 24, 2024 - Abstract #ASCO2024ASCO_1912;
P2
Cadonilimab plus lenvatinib showed promising antitumor activity in patients with advanced endometrial cancer who have experienced disease progression after prior systemic platinum-based therapy. The combination therapy had a favorable and manageable safety profile.
- Enweida (envafolimab) / 3DMed, Tracon Pharma, Ascletis, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Efficacy and safety of combination therapy with envafolimab and lenvatinib in patients with endometrial cancer after failure of first-line platinum-based therapy. (Hall A; Poster Bd #: 468) - Apr 24, 2024 - Abstract #ASCO2024ASCO_1909;
P2
Compared to the results from other intravenous anti-PD-1 antibody plus Lenvatinib in EC patients, Envafolimab with Lenvatinib had comparable efficacy and similar safety whilst a higher proportion of heavily pretreated patients were enrolled in this trial. Moreover, subcutaneous injection of Envafolimab plus Lenvatinib provided a more convenient dosing regimen in this population.
- Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Outcomes of reduced dosing of lenvatinib with pembrolizumab for advanced endometrial cancer. (Hall A; Poster Bd #: 459) - Apr 24, 2024 - Abstract #ASCO2024ASCO_1901;
In addition, those who received a lower starting dose experienced fewer dose reductions but no difference in dose discontinuation due to AE. Prospective studies of dose and schedule are needed to confirm these findings and define an optimal dosing strategy.
- Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Phase II study of pembrolizumab and lenvatinib in platinum sensitive recurrent ovarian cancer. (Hall A; Poster Bd #: 452) - Apr 24, 2024 - Abstract #ASCO2024ASCO_1894;
P2
Effect on survival and response to subsequent therapies is yet to be evaluated. Further research is essential to pinpoint the patient subset that can benefit the most from this combination.
- Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Biomarker analyses in patients with advanced renal cell carcinoma (aRCC) from the phase 3 CLEAR trial. (Hall B1) - Apr 24, 2024 - Abstract #ASCO2024ASCO_1800;
P3
Further research is essential to pinpoint the patient subset that can benefit the most from this combination. Background: In the primary analysis of CLEAR, lenvatinib + pembrolizumab (L+P) significantly improved efficacy vs sunitinib (S) in treatment-na
- Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Comparative effectiveness of first-line (1L) ipilimumab plus nivolumab (Ipi + Nivo) versus immune checkpoint inhibitors + tyrosine kinase inhibitors (ICI + TKI) in patients (pts) with intermediate or poor (I/P) risk metastatic clear cell renal cell carcinoma (mccRCC). (Hall A; Poster Bd #: 252) - Apr 24, 2024 - Abstract #ASCO2024ASCO_1722;
In this study rwOS was comparable between pts receiving Ipi + Nivo vs. ICI + TKI Rx while rwTTNT was better with ICI + TKI. These data can help clinicians in pts counseling, and treatment selection.
- sitravatinib (MGCD516) / BeiGene, Opdivo (nivolumab) / BMS
A phase II trial of sitravatinib plus nivolumab after progression on prior immune checkpoint inhibitor (ICI) in patients with metastatic clear cell renal cell carcinoma (ccRCC). (Hall A; Poster Bd #: 237) - Apr 24, 2024 - Abstract #ASCO2024ASCO_1708;
P2
In this small phase 2 trial with limited sample size due to early termination, sitravatinib plus nivolumab demonstrated a manageable safety profile and produced modest clinical benefit. The observed responses occurred in patients who did not receive prior treatment with cabozantinib or lenvatinib.
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
Efficacy of post-lenvatinib treatments in patients (pts) with advanced renal cell carcinoma (aRCC). (Hall A; Poster Bd #: 233) - Apr 24, 2024 - Abstract #ASCO2024ASCO_1704;
In this analysis, we demonstrate modest activity of TKI-based therapy post-lenvatinib exposure. Our study highlights the need for improved treatment options for pts progressing on lenvatinib-based therapies.
- Welireg (belzutifan) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Belzutifan plus lenvatinib (len) for Chinese patients (pts) with previously treated advanced clear cell renal cell carcinoma (ccRCC): Preliminary results of cohort 1 of the phase 1 LITESPARK-010 study. (Hall A; Poster Bd #: 232) - Apr 24, 2024 - Abstract #ASCO2024ASCO_1703;
P1
Preliminary data from the belzutifan + len showed promising antitumor activity in Chinese pts with previously treated ccRCC. The safety of belzutifan 120 mg + len 20 mg was consistent with the safety profiles of the individual drugs.